NGL Fine-Chem Ltd. Reports Audited Earnings Results for the Third Quarter and Nine Months Ended December 31, 2013
January 29, 2014 at 06:47 pm IST
Share
NGL Fine-Chem Ltd. reported audited earnings results for the third quarter and nine months ended December 31, 2013. For the quarter, the company reported net sales/income from operations of INR 174.031 million compared to INR 143.359 million a year ago. Profit from operations before other income, finance costs was INR 13.991 million compared to INR 11.629 million a year ago. Profit from ordinary activities before tax was INR 10.585 million compared to INR 8.846 million a year ago. Net profit was INR 10.585 million or INR 1.71 per basic and diluted share compared to INR 8.848 million or INR 1.43 per basic and diluted share for the last year.
For the nine months, the company reported net sales/income from operations of INR 575.297 million compared to INR 381.987 million a year ago. Profit from operations before other income, finance costs was INR 67.842 million compared to INR 36.661 million a year ago. Profit from ordinary activities before tax was INR 59.008 million compared to INR 29.154 million a year ago. Net profit was INR 69.008 million or INR 9.55 per basic and diluted share compared to INR 29.154 million or INR 4.72 per basic and diluted share for the last year.
NGL Fine-Chem Limited is an India-based company, which is a manufacturer of pharmaceuticals and intermediates for use in veterinary and human health. The Company caters to various global companies to custom manufacture pharmaceuticals. Its products include APIs Animal Health, APIs Human Health, Intermediates and Specialty Chemicals and Finished Dosage Form. The APIs Animal Health products include Homidium Chloride, Nitroxynil, Clorsulon, Parvaquone, Buparvaquone, Isometamidium Chloride Hydrochloride, Toldimfos Sodium, Butaphosphan, Imidocarb Dipropionate, Triclabendazole, Rafoxanide, Diminazene Aceturate, S-Methoprene, Carprofen and others. The APIs Human Health products include Nitazoxanide and Atovaquone. The Intermediates and Specialty Chemicals product includes 1,4,7-Trimethyl-1,4,7-Triazacylononane and N-Ethyl Glucamine. The Finished Dosage Form products include Diminazene Aceturate Granules and Homidium Chloride Tablets. It has manufacturing plants located around Mumbai.